bluuebunny/crossref_metadata_2025_split huggingface dataset:
FBI‐1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo
Authors: Fang Feng , Yang Lianyue , Tao Yiming , Qin Wei 
Published: June 2011

AbstractBACKGROUND:The so‐called factor that binds to inducer of short transcripts‐1 (FBI‐1) purportedly plays an important role in tumorigenesis; however, its role in hepatocellular carcinoma (HCC) remains unknown. The objective of this study was to investigate the expression level, clinical relevance, and biologic function of FBI‐1 in HCC.METHODS:Real‐time quantitative reverse transcriptase‐polymerase chain reaction analysis, Western blot analysis, and immunohistochemical staining were used to detect expression levels of FBI‐1 and to analyze its relation to clinicopathologic parameters and to the prognosis of patients with HCC. In addition, the biologic functions of FBI‐1 in regulating cell proliferation, migration, and reaction to chemotherapy were detected by using HepG2 cells and SMMC‐7721 cells; subsequently, the molecular mechanism of FBI‐1 also was investigated. Finally, a xenograft mouse model was used to validate the observations obtained from in vitro studies.RESULTS:Expression levels of FBI‐1 messenger RNA and protein were elevated significantly in HCC tissues compared with adjacent nontumorous liver tissues (ANLTs). Increased FBI‐1 expression was correlated with multiple tumor nodes, Edmondson‐Steiner grade, and a poor prognosis in patients with HCC (P < .05). In vitro studies revealed that FBI‐1 was capable of promoting cell proliferation (but not cell migration) by regulating the cell cycle regulation proteins p53, p21, and p27. In addition, FBI‐1 could inhibit cell death induced by 5‐fluorouracil or doxorubicin through suppressing the activation of p53. Consistent with the in vitro data, FBI‐1 was capable of promoting cell proliferation and enhancing chemotherapy resistance of HCC in vivo.CONCLUSIONS:The current findings indicated that FBI‐1 plays an important role in HCC carcinogenesis and chemotherapy tolerance, and FBI‐1 may served as a novel prognostic marker and therapeutic target for HCC. Cancer 2012;. © 2011 American Cancer Society.
Reirradiation and hyperthermia for radiation‐associated sarcoma
Authors: de Jong Marianne A. A. , Oldenborg Sabine , Bing Oei S. , Griesdoorn Vanessa , Kolff M. Willemijn , Koning Caro C. E. , van Tienhoven Geertjan 
Published: June 2011

AbstractBACKGROUND:The objective of this study was to evaluate the role of reirradiation and hyperthermia in the treatment of radiation‐associated sarcoma (RAS) in the thoracic region, which is an increasing, yet extremely rare condition with a poor prognosis.METHODS:Between 1979 and 2009, 16 patients with RAS in the thoracic region were treated in the Academic Medical Center and the Institute Verbeeten with reirradiation and hyperthermia. In 13 patients, this treatment was given for unresectable disease and 3 times after resection as adjuvant treatment. The median latency period between the original malignancy diagnosis and the RAS diagnosis was 86 months (range 19‐212 months). Histology was angiosarcoma in 11 patients (69%). The literature on reirradiation with or without hyperthermia for RAS was reviewed.RESULTS:The median survival was 15.5 months (range, 3‐204 months). Four patients were not evaluable for response. The response rate for the remaining 12 patients was 75% (7 complete responses and 2 partial responses). Six patients remained free of local failure until death (5 months and 7 months) or last follow‐up (8 months, 11 months, 39 months, and 68 months).CONCLUSIONS:The current study indicates that combined reirradiation and hyperthermia for RAS in the thoracic region is feasible. The high response rate and the possibility of durable local control suggest that this treatment is promising. Cancer 2012;. © 2011 American Cancer Society.
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
Authors: Edeline Julien , Boucher Eveline , Rolland Yan , Vauléon Elodie , Pracht Marc , Perrin Christophe , Le Roux Catherine , Raoul Jean‐Luc 
Published: June 2011

AbstractBACKGROUND:A significant improvement in overall survival (OS) was demonstrated in patients with advanced hepatocellular carcinoma (HCC) who received sorafenib (Sor) in the Sorafenib HCC Assessment Randomized Protocol (SHARP) study, in contrast to a response rate (RR) of 2% assessed according to Response Evaluation Criteria in Solid Tumors (RECIST). Modified RECIST (mRECIST) were developed to assess the response in patients with HCC, based on measurement of viable tumor with arterial enhancement on a computed tomography (CT) scan. In the current study, mRECIST were evaluated and were compared with RECIST in patients who received Sor for advanced HCC.METHODS:The authors retrospectively analyzed 53 patients who received Sor for advanced HCC. Patients must to have undergone a 4‐phase CT scan before treatment and repeatedly thereafter. CT scans were analyzed using RECIST 1.1 and mRECIST.RESULTS:The rates of objective response (OR), stable disease (SD), and progressive disease (PD) were 2%, 79%, and 19%, respectively, according to RECIST and 23%, 57%, and 21%, respectively, according to mRECIST (P < .001). Patients who achieved an OR according to mRECIST had a longer OS than nonresponding patients with SD or PD (median OS, 18 months and 8 months, respectively; P = .013). In the 42 patients who achieved SD according to RECIST, OS differed depending on tumor response according to mRECIST, with a median OS of 17 months, 10 months, and 4 months for patients who achieved an OR (n = 11), SD (n = 29), and PD (n = 2), respectively (P = .016).CONCLUSIONS:The current series validated mRECIST in patients who received Sor for advanced HCC. The majority of patients who had SD according to RECIST had a different prognosis according to mRECIST. The results indicated that, for patients with HCC, mRECIST should be used for the standard assessment of treatment efficacy, particularly in patients who are receiving antiangiogenic drugs. Cancer 2012;. © 2011 American Cancer Society.
Novel, chimeric, cancer‐specific, and radiation‐inducible gene promoters for suicide gene therapy of cancer
Authors: Xiong Jie , Sun Wen‐jie , Wang Wei‐feng , Liao Zheng‐kai , Zhou Fu‐xiang , Kong Hai‐yan , Xu Yu , Xie Cong‐hua , Zhou Yun‐feng 
Published: June 2011

AbstractBACKGROUND:Although the promoter of the human telomerase reverse transcriptase (hTERT) gene has been widely used in gene therapy for targeted cancer cells, it has some limitations for clinical use because of its low activity and potential toxicity to certain normal cells. To overcome these defects, the authors generated novel chimeric hTERT promoters that contained the radiation‐inducible sequence CC(A/T)6GG (known as CArG elements).METHODS:Chimeric hTERT promoters were synthesized that contained different numbers of CArG elements, and the activity of chimeric promoters was assessed in different cancer cell lines and normal cells. The potential of selected promoters to successfully control horseradish peroxidase (HRP) and prodrug indole‐3‐acetic acid (IAA) suicide gene therapy was tested in vitro and in vivo.RESULTS:The promoter activity assays indicated that the synthetic promoter that contained 6 repeating CArG units had the best radiation inducibility than any other promoters that contained different numbers of CArG units, and the chimeric promoters retained their cancer‐specific characteristics. The chimeric promoter was better at driving radiation‐inducible gene therapy than the control promoters. The sensitizer enhancement ratio of the chimeric promoter system determined by clonogenic assay was higher, and the chimeric promoter system resulted in a significantly higher apoptotic level compared with other promoter systems. The combination of chimeric/promoter‐mediated gene therapy and radiotherapy significantly inhibited tumor volume in a xenograft mouse model and resulted in a significant prolongation of survival in mice.CONCLUSIONS:The current results indicated that a combinational cancer‐specific promoter system that is responsive to irradiation has great potential for improving the efficacy of cancer treatment. Cancer 2011;. © 2011 American Cancer Society.
Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data
Authors: Jagsi Reshma , Abrahamse Paul , Hawley Sarah T. , Graff John J. , Hamilton Ann S. , Katz Steven J. 
Published: June 2011

AbstractBACKGROUND:Surveillance, Epidemiology, and End Results (SEER) registry data have been used to suggest underuse and disparities in receipt of radiotherapy. Prior studies have cautioned that SEER may underascertain radiotherapy but lacked adequate representation to assess whether underascertainment varies by geography or patient sociodemographic characteristics. The authors sought to determine rates and correlates of underascertainment of radiotherapy in recent SEER data.METHODS:The authors evaluated data from 2290 survey respondents with nonmetastatic breast cancer, aged 20 to 79 years, diagnosed from June of 2005 to February 2007 in Detroit and Los Angeles and reported to SEER registries (73% response rate). Survey responses regarding treatment and sociodemographic factors were merged with SEER data. The authors compared radiotherapy receipt as reported by patients versus SEER records. The authors then assessed correlates of radiotherapy underascertainment in SEER.RESULTS:Of 1292 patients who reported receiving radiotherapy, 273 were coded as not receiving radiotherapy in SEER (underascertained). Underascertainment was more common in Los Angeles than in Detroit (32.0% vs 11.25%, P < .001). On multivariate analysis, radiotherapy underascertainment was significantly associated in each registry (Los Angeles, Detroit) with stage (P = .008, P = .026), income (P < .001, P = .050), mastectomy receipt (P < .001, P < .001), chemotherapy receipt (P < .001, P = .045), and diagnosis at a hospital that was not accredited by the American College of Surgeons (P < .001, P < .001). In Los Angeles, additional significant variables included younger age (P < .001), nonprivate insurance (P < .001), and delayed receipt of radiotherapy (P < .001).CONCLUSIONS:SEER registry data as currently collected may not be an appropriate source for documentation of rates of radiotherapy receipt or investigation of geographic variation in the radiation treatment of breast cancer. Cancer 2011;. © 2011 American Cancer Society.
Exemestane versus anastrozole as front‐line endocrine therapy in postmenopausal patients with hormone receptor‐positive, advanced breast cancer
Authors: Llombart‐Cussac Antonio , Ruiz Amparo , Antón Antonio , Barnadas Agustí , Antolín Silvia , Alés‐Martínez José E. , Álvarez Isabel , Andrés Raquel , García Saenz José A. , Lao Juan , Carrasco Eva , Cámara Carmen , Casas Isabel , Martín Miguel 
Published: June 2011

AbstractBACKGROUND:Several aromatase inhibitor studies have reported variations in the inhibitory potency of these agents that could lead to differences in clinical outcomes. In the current study, the authors formally evaluated the activity of anastrozole and exemestane in postmenopausal women with hormone‐responsive, advanced breast cancer.METHODS:Postmenopausal women who had measurable disease according to Response Evaluation Criteria in Solid Tumors and had not received previous endocrine therapy for advanced breast cancer were randomized to receive either oral exemestane 25 mg daily or oral anastrozole 1 mg daily until they had disease progression. The primary endpoint was the objective response rate (ORR), and secondary endpoints included the clinical benefit rate (CBR), time to progression (TTP), overall survival, and safety. Crossover to the other aromatase inhibitor was permitted at the time of disease progression; ORR, CBR, and TTP after second‐line treatment also were explored.RESULTS:In total, 103 patients were enrolled. The median patient age was 71.6 years, 52.4% of patients had visceral disease, and 75.8% of patients had ≥2 disease sites. Half of the patients had received previous tamoxifen, and 60% had received previous chemotherapy. The efficacy observed in the exemestane and anastrozole groups was an ORR of 36.2% and 46%, respectively; a CBR of 59.6% and 68%, respectively, and a TTP of 6.1 months and 12.1 months, respectively. At progression, 28 patients crossed over to the other aromatase inhibitor, including 16 patients who switched to exemestane (CBR, 43.7%; TTP, 4.4 months) and 12 patients who switched to anastrozole (CBR, 8.3%; TTP, 2 months). Both drugs were generally well tolerated, and no study drug‐related serious adverse events were reported.CONCLUSIONS:In this phase 2 randomized trial, no significant differences in clinical activity were observed in favor of exemestane to justify a superiority phase 3 trial design in the first‐line setting. Cancer 2012;. © 2011 American Cancer Society.
Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma
Authors: Dikken Johan L. , Coit Daniel G. , Klimstra David S. , Rizk Nabil P. , van Grieken Nicole , Ilson David , Tang Laura H. 
Published: June 2011

AbstractBACKGROUND:In the seventh edition of the American Joint Committee on Cancer (AJCC) staging system for esophageal cancer, tumor grade was introduced as an independent determinant of stage grouping in early stage tumors. With the significantly lower prognosis for poorly differentiated early stage adenocarcinomas, patients with these tumors may become candidates for neoadjuvant therapy given an accurate identification of these tumors with preoperative staging. The objective of the current study was to investigate the accuracy of preoperative histopathologic grading and the effect of preoperative grade on tumor stage/prognostic grouping.METHODS:Preoperative tumor grade was compared with postoperative tumor grade in 427 patients who underwent surgery without receiving neoadjuvant therapy for adenocarcinoma of the esophagus. The impact of preoperative tumor grade on stage/prognostic grouping was investigated.RESULTS:The overall accuracy of preoperative tumor grade assessment was 76% when unknown differentiation was regarded as well/moderately differentiated as recommended by the AJCC, whereas accuracy was 73% after the exclusion of tumors with unknown grade. In patients who have tumors classified as T1 or T2 and lymph node‐negative (N0) (T1‐T2N0) disease, 16% were assigned to a lower stage group based on preoperative pathology, whereas 5% were assigned to a higher stage group. In the T1‐T2N0 group, sensitivity for detecting a poorly differentiated tumor was 0.43 (95% confidence interval [CI], 0.30‐0.56), whereas specificity was 0.94 (95% CI, 0.90‐0.98).CONCLUSIONS:With increasing use of neoadjuvant therapy, the accuracy of preoperative biopsy assessment has become increasingly important. In the current study, the accuracy of preoperative tumor grade assessment was 73%, leading to changes in AJCC stage/prognostic group in 21% of patients with T1‐T2N0 esophageal adenocarcinomas. The authors concluded that caution should be exhibited in staging patients with esophageal adenocarcinoma based on preoperative biopsy data. Cancer 2011;. © 2011 American Cancer Society.
Identification of tissue of origin in body fluid specimens using a gene expression microarray assay
Authors: Stancel Gregory A. , Coffey Donna , Alvarez Karla , Halks‐Miller Meredith , Lal Anita , Mody Dina , Koen Tracy , Fairley Todd , Monzon Federico A. 
Published: June 2011

AbstractBACKGROUND:Body fluid specimens may be the first and only pathologic specimen for clinical evaluation in metastatic cancer cases. The challenge of identifying the tissue of origin in metastatic cancer has led to the emergence of molecular‐based assays, such as the microarray‐based Pathwork Tissue of Origin gene expression test. The ability to use body fluid specimens in this test would be valuable in providing diagnoses to cancer patients without clearly identifiable primary sites. In the current study, the authors evaluated the Tissue of Origin Test for use with malignant effusion specimens.METHODS:A total of 27 metastasis‐positive body fluid specimens from different body sites, including pleural, ascites, pericardial, and pelvic wash fluids, were obtained from patients with known diagnoses. Nine specimens from nonmalignant body fluids were included as controls. RNA was extracted from formalin‐fixed, paraffin‐embedded (FFPE) tissue and gene expression analysis was performed with the Tissue of Origin Test.RESULTS:Seventeen of 27 metastasis‐positive samples were non‐necrotic with ≥60% tumor and yielded sufficient RNA. Of these samples, 94.1% (16 of 17) were in agreement with the available diagnosis. Of the 9 negative control samples evaluated, 7 (77.8%) demonstrated microarray expression profiles most similar to lymphoma, which is consistent with the predominance of inflammatory cells in these specimens.CONCLUSIONS:The results of the current study demonstrated that FFPE cell blocks from cytologic body fluid specimens yield adequate diagnostic material for the Pathwork test and can be used in the workup of patients with unknown primary tumors. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.
Photoisomerization around a Fulvene Double Bond: Coherent Population Transfer to the Electronic Ground State?
Authors: Ioffe Ilya , Dobryakov Alexander L. , Granovsky Alexander A. , Ernsting Nikolaus P. , Pérez Lustres J. Luis 
Published: June 2011

AbstractPhotoisomerization around a central fulvene‐type double bond is known to proceed through a conical intersection at the perpendicular geometry. The process is studied with an indenylidene–dihydropyridine model compound, allowing the use of visible excitation pulses. Transient absorption shows that 1) stimulated emission shifts to the red and loses oscillator strength on a 50 fs timescale, and 2) bleach recovery is highly nonexponential and not affected by solvent viscosity or methyl substitution at the dihydropyridine ring. Quantum‐chemical calculations are used to explain point 1 as a result of initial elongation of the central CC bond with mixing of S2 and S1 states. From point 2 it is concluded that internal conversion of S1→S0 does not require torsional motion to the fully perpendicular state. The S1 population appears to encounter a sink on the torsional coordinate before the conical intersection is reached. Rate equations cannot model the observed ground‐state recovery adequately. Instead the dynamics are best described with a strongly damped oscillatory contribution, which could indicate coherent S1–S0 population transfer.
Compressibility of Gas Hydrates
Authors: Manakov Andrey Yu. , Likhacheva Anna Yu. , Potemkin Vladimir A. , Ogienko Andrey G. , Kurnosov Alexander V. , Ancharov Aleksei I. 
Published: June 2011

AbstractExperimental data on the pressure dependence of unit cell parameters for the gas hydrates of ethane (cubic structure I, pressure range 0–2 GPa), xenon (cubic structure I, pressure range 0–1.5 GPa) and the double hydrate of tetrahydrofuran+xenon (cubic structure II, pressure range 0–3 GPa) are presented. Approximation of the data using the cubic Birch–Murnaghan equation,P=1.5B0[(V0/V)7/3−(V0/V)5/3], gave the following results: for ethane hydrateV0=1781 Å3,B0=11.2 GPa; for xenon hydrateV0=1726 Å3,B0=9.3 GPa; for the double hydrate of tetrahydrofuran+xenonV0=5323 Å3,B0=8.8 GPa. In the last case, the approximation was performed within the pressure range 0–1.5 GPa; it is impossible to describe the results within a broader pressure range using the cubic Birch–Murnaghan equation. At the maximum pressure of the existence of the double hydrate of tetrahydrofuran+xenon (3.1 GPa), the unit cell volume was 86 % of the unit cell volume at zero pressure. Analysis of the experimental data obtained by us and data available from the literature showed that 1) the bulk modulus of gas hydrates with classical polyhedral structures, in most cases, are close to each other and 2) the bulk modulus is mainly determined by the elasticity of the hydrogen‐bonded water framework. Variable filling of the cavities with guest molecules also has a substantial effect on the bulk modulus. On the basis of the obtained results, we concluded that the bulk modulus of gas hydrates with classical polyhedral structures and existing at pressures up to 1.5 GPa was equal to (9±2) GPa. In cases when data on the equations of state for the hydrates were unavailable, the indicated values may be recommended as the most probable ones.
Development of a hybrid sputtering/evaporation process for Cu(In,Ga)Se2 thin film solar cells
Authors: Acciarri M. , Binetti S. , Le Donne A. , Lorenzi B. , Caccamo L. , Miglio L. , Moneta R. , Marchionna S. , Meschia M. 
Published: June 2011

AbstractIn this paper we report a new method for Cu(In,Ga)Se2 deposition for solar cell application. Differently from the common co‐evaporation process, an alterative approach for thin film Cu(In,Ga)Se2 has been tested: the sputtering deposition of metal elements combined with the selenium evaporation. We have studied the relationships between the growth parameters of our hybrid sputtering/evaporation method and the chemical‐physical properties of the CIGS films. The cells are completed with a CdS buffer layer deposited by chemical bath deposition and ZnO + ITO deposited by RF sputtering. Test solar cells of 0.5 cm2 have shown an efficiency of 10% and 2.5% on glass and stainless steel substrate respectively. (© 2011 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim)
Investigation on the regeneration of Z‐cut KDP crystals
Authors: Zhong De‐Gao , Bing Teng , Yu Zheng‐He , Wang Shu‐Hua , Jiang Xue‐Jun , He Lin‐Xiang , Huang Wan‐Xia 
Published: June 2011

AbstractThe regeneration of Z‐cut KDP crystals is explored by analyzing the growth of thin surface layers formed. The structural defects and crystalline perfection of the thin surface layers are evaluated by white‐beam synchrotron radiation topography and high‐resolution X‐Ray diffraction respectively. It shows that the thin surface layers have the same crystal structure as KDP crystal. There are large numbers of defects in thin surface layers and the crystalline quality is very poor. The growth velocity of thin surface layers is firstly accurately measured by a newly‐designed in‐situ crystal growth observation setup. It is found that the growth velocity of the thin surface layers strongly depends on the flow rate of the growth solution. The hindering effect of pyrophosphate (K4P2O7) on the growth of the thin surface layers is discussed. (© 2011 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim)